Search Results - "Bhansali, S.G."

Combined 2D and 3D-QSAR, molecular modelling and docking studies of pyrazolodiazepinones as novel phosphodiesterase 2 inhibitors by Bhansali, S.G., Kulkarni, V.M.

“…Selective inhibition of phosphodiesterase 2 (PDE2) in cells where it is located elevates cyclic guanosine monophosphate (cGMP) and acts as novel analgesic with…”
Get full text

455PPHASE I STUDY OF LEE011 (CDK4/6 INHIBITOR) IN PATIENTS WITH MALIGNANT RHABDOID TUMORS, NEUROBLASTOMA, AND CYCLIN D–CDK4/6 PATHWAY-ACTIVATED TUMORS by Geoerger, B., Bourdeaut, F., Dubois, S.G., Dewire, M.D., Marabelle, A., Pearson, A.D., Modak, S., Kan, R., Matano, A., Bhansali, S.G., Parasuraman, S., Chi, S.N.

“…Abstract Aim: SMARCB1 mutations are observed in the majority of malignant rhabdoid tumors (MRTs) rendering them dependent on cyclin D1 (CCND1) for genesis and…”
Get full text

Phase Ib/Ii Study of Lee011 (Cdk4/6 Inhibitor) and Lgx818 (Braf Inhibitor) in Braf-Mutant Melanoma by Taylor, M., Sosman, J., Gonzalez, R., Carlino, M.S., Kittaneh, M., Lolkema, M.P., Miller, W., Marino, A., Zhang, V., Bhansali, S.G., Parasuraman, S., Postow, M.A.

Get full text

1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA by Taylor, M., Sosman, J., Gonzalez, R., Carlino, M.S., Kittaneh, M., Lolkema, M.P., Miller, W., Marino, A., Zhang, V., Bhansali, S.G., Parasuraman, S., Postow, M.A.

“…Abstract Aim: Despite improvements in BRAF-mutant melanoma therapy, resistance is problematic. The cyclin D–CDK4/6–INK4A–Rb pathway is frequently dysregulated…”
Get full text

Phase I Study of Lee011 (Cdk4/6 Inhibitor) in Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Cyclin D–Cdk4/6 Pathway-Activated Tumors by Geoerger, B., Bourdeaut, F., Dubois, S.G., Dewire, M.D., Marabelle, A., Pearson, A.D., Modak, S., Kan, R., Matano, A., Bhansali, S.G., Parasuraman, S., Chi, S.N.

Get full text